

Hu-uPAR-DII-DIII Binding




FIG. 1A

Hu-uPAR-DIII Binding




FIG. 1B




FIG. 2A




FIG. 2B












FIG. 3

4/12

Human scIL-12**FIG. 4A***p35-SA***FIG. 4B***p35 KiH (Fab)***FIG. 4C***p40-ScFv***FIG. 4D***p35-ScFv2***FIG. 4E***p35-KiH (ScFv)***FIG. 4F***p40-Fab***FIG. 4G***p40-IgG***FIG. 4H**

5/12

Tumor and serum pharmacokinetics from PET/CT imaging of radiolabeled tumor-targeted subunits

**FIG. 5A****FIG. 5B**




FIG. 6A




FIG. 6B






FIG. 7

8/12

**FIG. 8A****FIG. 8B**




FIG. 9

10/12




FIG. 10

11/12




FIG. 11

12/12




FIG. 12